• Innate Pharma posted Q1 2026 revenue of EUR 2.6 million, up from EUR 1.2 million in Q1 2025, driven mainly by recognition of payments under AstraZeneca and Sanofi collaboration and license agreements.
• Cash, cash equivalents, and financial assets totaled EUR 25.4 million at March 31, 2026; financial liabilities were EUR 20.3 million.
• Cash runway extended to end of Q3 2026.
• Phase 3 TELLOMAK-3 trial of lacutamab in cutaneous T-cell lymphomas remained slated for H2 2026, contingent on securing non-dilutive funding under negotiation, including pharma partnerships and royalty financing.
• AstraZeneca-led Phase 3 PACIFIC-9 trial including monalizumab stayed on track for a data readout in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.